Feature Article | Kirkland’s EIT Pharma Announces Milestone for Drug Treating Chronic Hepatitis D

The FDA has accepted EIT Pharma's New Drug Application for lonafarnib, putting a potential first oral therapy for chronic hepatitis D into formal review. This piece covers what the milestone means for a disease with no FDA-approved oral treatments in the U.S., the D-LIVR study behind the submission, and why CEO Leen Kawas points to oral dosing and room-temperature storage as practical advantages for patients and providers.

Read the Full Article Here